Home > > > > > Report Detail

Diabetic Cardiomyopathy - Pipeline Insight, 2021

Publisher Name :
Date: 10-Feb-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Diabetic Cardiomyopathy - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Diabetic Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Diabetic Cardiomyopathy Understanding

Diabetic Cardiomyopathy: Overview

Diabetic cardiomyopathy is a type of cardiovascular damage present in patients suffering from diabetes. It is characterized by myocardial dilatation and hypertrophy as well as a decrease in the systolic and diastolic functions of the left ventricle, and its presence is independent of the coexistence of ischemic heart disease or hypertension. Existence of this condition in a diabetic patient may have several therapeutic implications including: improving glycemic control, earlier use of calcium channel blockers (CCBs), ACE inhibitors and ARBs, exercise training, lipid-lowering therapy, and antioxidant and insulin-sensitizing drugs. Increasing evidence suggests that hyperglycemia is central to the pathogenesis of diabetic cardiomyopathy, which triggers a series of maladaptive events leading to cardiomyocyte apoptosis, collagen deposition, and cardiac fibrosis.

"Diabetic Cardiomyopathy - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Cardiomyopathy pipeline landscape is provided which includes the disease overview and Diabetic Cardiomyopathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Cardiomyopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Cardiomyopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Cardiomyopathy.

Diabetic Cardiomyopathy Emerging Drugs Chapters

This segment of the Diabetic Cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Cardiomyopathy Emerging Drugs

- IMB-1018972: Imbria Pharmaceuticals

Mechanism of Action: Partial fatty acid oxidation inhibitors. Currently under phase 2 of clinical trials for the treatment of diabetic cardiaomyopathy

- AT-001: Applied Therapeutics

AT-001 is an investigational, novel Aldose Reductase Inhibitor (ARI) being developed as an oral therapy for the treatment of Diabetic Cardiomyopathy (DbCM). Applied Therapeutics initiated a Phase 3 registrational study in DbCM with this potent and selective agent in September 2019.

Further product details are provided in the report……..

Diabetic Cardiomyopathy: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Diabetic Cardiomyopathy

There are approx. 3+ key companies which are developing the therapies for Diabetic Cardiomyopathy. The companies which have their Diabetic Cardiomyopathy drug candidates in the mid to advanced stage, i.e. phase II include, Imbria Pharmaceuticals and others.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

- Late-stage products (Phase III)

- Mid-stage products (Phase II and Phase I/II)

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Route of Administration

Diabetic Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Subcutaneous

- Intravenous

- Oral

- Intramuscular

- Molecule Type

Products have been categorized under various Molecule types such as

- Small molecules

- Natural metabolites

- Monoclonal antibodies

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Cardiomyopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Cardiomyopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Cardiomyopathy drugs.

Diabetic Cardiomyopathy Report Insights

- Diabetic Cardiomyopathy Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Diabetic Cardiomyopathy Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Diabetic Cardiomyopathy drugs?

- How many Diabetic Cardiomyopathy drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Cardiomyopathy?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Cardiomyopathy therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Diabetic Cardiomyopathy and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Imbria Pharmaceuticals

- Applied Therapeutics

Key Products

- IMB-1018972

- AT-001

Diabetic Cardiomyopathy - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Diabetic Cardiomyopathy: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Diabetic Cardiomyopathy - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Diabetic Cardiomyopathy companies' collaborations, Licensing, Acquisition -Deal Value Trends
Diabetic Cardiomyopathy Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
AT-001: Applied Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
IMB-101897: Imbria Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Diabetic Cardiomyopathy Key Companies
Diabetic Cardiomyopathy Key Products
Diabetic Cardiomyopathy- Unmet Needs
Diabetic Cardiomyopathy- Market Drivers and Barriers
Diabetic Cardiomyopathy- Future Perspectives and Conclusion
Diabetic Cardiomyopathy Analyst Views
Diabetic Cardiomyopathy Key Companies
Appendix

List of Tables

Table 1 Total Products for Diabetic Cardiomyopathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Diabetic Cardiomyopathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Digoxin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 75
    According to our LPI (LP Information) latest study, the global Digoxin market size was valued at US$ 59 million in 2023. With growing demand in downstream market, the Digoxin is forecast to a readjusted size of US$ 73 million by 2030 with a CAGR of 3.2% during review period. The research report highlights the growth potential of the global Digoxin market. Digoxin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain op......
  • Global Heart Failure Drugs Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 116
    According to our LPI (LP Information) latest study, the global Heart Failure Drugs market size was valued at US$ million in 2023. With growing demand in downstream market, the Heart Failure Drugs is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Heart Failure Drugs market. Heart Failure Drugs are expected to show stable growth in the future market. However, product differentiatio......
  • Global Atorvastatin Calcium Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 138
    According to our LPI (LP Information) latest study, the global Atorvastatin Calcium market size was valued at US$ 214.2 million in 2023. With growing demand in downstream market, the Atorvastatin Calcium is forecast to a readjusted size of US$ 362 million by 2030 with a CAGR of 7.8% during review period. The research report highlights the growth potential of the global Atorvastatin Calcium market. Atorvastatin Calcium are expected to show stable growth in the future market. However, prod......
  • Global Rosuvastatin Calcium Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 139
    According to our LPI (LP Information) latest study, the global Rosuvastatin Calcium market size was valued at US$ 514.3 million in 2023. With growing demand in downstream market, the Rosuvastatin Calcium is forecast to a readjusted size of US$ 683.6 million by 2030 with a CAGR of 4.1% during review period. The research report highlights the growth potential of the global Rosuvastatin Calcium market. Rosuvastatin Calcium are expected to show stable growth in the future market. However, pr......
  • Global Atorvastatin Calcium Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 133
    According to our (Global Info Research) latest study, the global Atorvastatin Calcium market size was valued at USD 225.3 million in 2023 and is forecast to a readjusted size of USD 366.1 million by 2030 with a CAGR of 7.2% during review period. Atorvastatin calcium is a pharmaceutical raw material in the production of atorvastatin calcium drug (trade name: Lipitor), which is a prescription medicine that lowers the LDL cholesterol and triglycerides in the blood and can raise HDL choleste......
  • Global Rosuvastatin Calcium Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 132
    According to our (Global Info Research) latest study, the global Rosuvastatin Calcium market size was valued at USD 540.9 million in 2023 and is forecast to a readjusted size of USD 703.6 million by 2030 with a CAGR of 3.8% during review period. Rosuvastatin calcium (CAS 147098-20-2, molecular formula being C44H54CaF2N6O12S2) is the active pharmaceutical ingredient for the once-a-day dyslipidaemia treatment Crestor, it is one approved API which can be used to reduce the risk of heart att......
  • Cilostazol - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 118
    The global Cilostazol market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Cilostazol in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Cilostazol market. Injection Cilostazol, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Freeze-dried P......
  • Rosuvastatin - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 110
    Rosuvastatin medication is a statin that is used to lower bad cholesterol and prevent cardiovascular disease. It works by blocking an enzyme in the liver that makes cholesterol. It is taken by mouth and should be used together with dietary changes, exercise, and weight loss. It may also raise good cholesterol and lower triglycerides. It is sold under the brand name Crestor among others. It may be used when other statins have not worked well. The global Rosuvastatin market size is expected......
  • Global Congestive Heart Failure Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 19-Dec-2023        Price: US 3380 Onwards        Pages: 123
    Market Overview of Global Congestive Heart Failure Drugs market: According to our latest research, the global Congestive Heart Failure Drugs market looks promising in the next 5 years. As of 2022, the global Congestive Heart Failure Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Congestive heart failure is a serious and complex condition in which the heart muscles are either dam......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs